metabolic
Research Use OnlyNAD+ Injectable Pen
A pre-filled subcutaneous delivery device containing 250 mg of nicotinamide adenine dinucleotide (NAD+) per unit. Provided as a laboratory reference compound for investigation of NAD-dependent enzymatic and redox pathways. Sold for laboratory research and identification purposes only. Not for human consumption.
Research Use Only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
Quantity
Free shipping over $500
Paying by Zelle / Apple Cash
New to sending payment this way? It's quick, and your order is protected:
- Payment confirmed as soon as it lands — usually within minutes during business hours.
- Most orders ship the same day, cold-packed and discreet.
- Every order ships tracked, with an email at each step.
- Questions answered within hours by a real person.
If we ever can't fulfill your order, you're refunded within 1–2 business days.
NAD+ Injectable Pen
$450
Technical Data
Specifications
Technical Details
Quality Assurance
Certificate of Analysis
Certificate of Analysis
COA documentation is being prepared for this product.
Contact research@roehn.co for batch-specific testing data.
Verified Feedback
Reviews
Be the first to review
Every batch ships with a published 99% HPLC COA. Share your experience with the product quality, packaging, or delivery.
No reviews yet — yours could be the first.
Research Overview
About NAD+ Injectable Pen
The NAD+ Injectable Pen represents the next evolution in coenzyme delivery — a ready-to-use, pre-filled pen device that eliminates the reconstitution step required by traditional lyophilized formulations. Each pen contains 250mg of pharmaceutical-grade nicotinamide adenine dinucleotide in a stabilized aqueous solution, delivered via a spring-loaded subcutaneous injection mechanism with a 31-gauge needle.
The pen format addresses a key limitation of conventional NAD+ administration: the complexity of reconstitution and the risk of dosing variability inherent in manual preparation. By providing a fixed-dose, factory-calibrated delivery system, the NAD+ Pen ensures consistent bioavailability across administrations while reducing preparation time from minutes to seconds.
Research into subcutaneous NAD+ delivery has demonstrated favorable pharmacokinetic profiles compared to oral precursor supplementation, with more direct tissue bioavailability. The pen's controlled delivery rate optimizes absorption kinetics, potentially reducing the discomfort sometimes associated with rapid subcutaneous NAD+ administration. Cold-chain logistics from manufacturing through delivery ensure compound stability throughout the supply chain.
